PDD Holdings Q4 2025 Earnings Report Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy PDD?
Source: seekingalpha
- Earnings Miss: PDD Holdings reported a Q4 2025 non-GAAP EPS of $2.53, missing expectations by $0.52, indicating pressure on profitability that could affect investor confidence.
- Revenue Growth Weakness: The company's revenue for Q4 was $17.72 billion, a 12% year-over-year increase, yet it fell short of market expectations by $390 million, reflecting challenges from intensified market competition and slowing consumer spending.
- Online Marketing Revenue Growth: Revenue from online marketing services and others reached RMB 60.01 billion (approximately $8.58 billion), a 5% increase from the same quarter in 2024, indicating stability in advertising revenue despite overall revenue misses.
- Improved Cash Flow: As of December 31, 2025, PDD's cash, cash equivalents, and short-term investments totaled RMB 422.3 billion (approximately $60.4 billion), a significant increase from RMB 331.6 billion in 2024, showcasing positive progress in liquidity management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PDD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PDD
Wall Street analysts forecast PDD stock price to rise
11 Analyst Rating
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 94.970
Low
118.00
Averages
146.39
High
167.00
Current: 94.970
Low
118.00
Averages
146.39
High
167.00
About PDD
PDD Holdings Inc. is a multinational commerce company that owns and operates a portfolio of businesses. The Company is focused on bringing businesses and people into the digital economy, which benefits local communities and small businesses from improved productivity and new opportunities. The Company has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses. Its Pinduoduo platform provides buyers with a comprehensive selection of value-for-money merchandise and fun and interactive shopping experiences. The Temu, a global e-commerce platform which brings together buyers, merchants, manufacturers, and brands from around the world, offers a selection of merchandise in product categories such as apparel, electronic appliances, household goods, sports and fitness, tools and home improvement, and pet supplies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Undervalued Stocks to Consider Now
- Pfizer's Current Status: Pfizer's stock is currently priced around $25, and despite a 1% increase this year, investors have seen a 37% decline over the past five years due to slowing growth and patent expirations; however, the company is actively expanding its pipeline through acquisitions like Metsera, which could improve future performance.
- Novo Nordisk's Challenges: Novo Nordisk's GLP-1 drugs, Wegovy and Ozempic, have been approved and are generating significant revenue, but rising competition has led to a 4% decline in sales in the first quarter; nevertheless, strong demand for Wegovy and promising results from a higher-dose version may enhance future market share.
- PDD Holdings' Resilience: PDD Holdings' stock has dropped 17% this year, currently trading around $95, yet despite facing tariffs and trade uncertainties, sales for the last three months of 2025 increased by 12% to $17.7 billion, demonstrating the company's resilience, with potential for recovery if trade conditions improve.
- Investment Opportunities: Pfizer, Novo Nordisk, and PDD Holdings are all trading below their projected future earnings, with Pfizer at a P/E of 9, Novo Nordisk at 14, and PDD Holdings at just 8, presenting attractive buying opportunities for long-term investors amid current undervaluation.
See More
Chinese Stocks Rally Ahead of Trump-Xi Summit
- Market Recovery: Major Chinese companies including Alibaba, PDD, NetEase, and JD.com saw stock gains between 3% and 7% on Wednesday, reflecting market optimism ahead of the upcoming Trump-Xi summit.
- Small Caps Surge: Smaller Chinese firms like Dreamland Limited, Oriental Culture, and Antelope Enterprise experienced significant stock increases ranging from 25% to 67%, indicating strong investor interest and confidence in these companies.
- Summit Significance: The meeting between Trump and Xi marks their first encounter since 2017, with discussions expected to cover critical topics such as trade, policies, and national security, potentially providing clarity for global markets on future business conditions.
- Market Expectations: Investors on social media express optimism about the summit's outcomes, anticipating potential new tech deals between the U.S. and China, particularly involving Alibaba and Nvidia, which could attract significant market attention.
See More
Shein Accuses Temu of Large-Scale Copyright Infringement
- Copyright Infringement Allegations: Shein accuses Temu of using thousands of its photos to promote copies of its clothing, attempting to gain an unfair competitive advantage, highlighting the fierce rivalry in the global e-commerce market.
- Legal Counterclaims: Temu has dropped its defense against Shein's copyright claims over nearly 2,300 photos and has counterclaimed for damages after being forced to remove numerous product listings, illustrating the complexity of the legal battle.
- Competition Law Dispute: Temu alleges that Shein violated competition law by tying fast-fashion suppliers to exclusive agreements, with a trial on this matter scheduled for next year, which could impact industry supply chain dynamics.
- Changing Market Conditions: The removal of U.S. customs exemptions on low-value e-commerce parcels poses challenges for Shein and Temu's rapid expansion in international markets, potentially negatively affecting future growth.
See More
Analysis of VXUS ETF's 52-Week Price Fluctuations
- Price Range Analysis: The VXUS ETF has a 52-week low of $64.6035 and a high of $85.32, with the last trade at $85.19, indicating stability near its high point, which may attract investor interest in its price movements.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market sentiment.
See More
Three Growth Stocks to Consider Now
- Novo Nordisk's Challenges and Opportunities: Despite a 36% drop in share price over the past year, Novo Nordisk maintains strong profitability with a 33% gross margin and powerful assets like Ozempic and Wegovy, positioning it to benefit from growth in the GLP-1 market in the future.
- PDD Holdings' Market Potential: PDD Holdings has seen a 12% decline in stock price over the past year, yet reported a 12% revenue growth in the last three months of 2025, demonstrating resilience amid economic uncertainty, with Temu's popularity providing a foundation for future recovery.
- Intuit's Value Recovery: Although Intuit's stock has fallen 36% in the past year, its latest quarterly results show a 17% revenue increase, and its strong brand presence in accounting and tax software suggests it can leverage AI to enhance value moving forward.
- Investor Patience Rewarded: These three stocks currently have forward P/E ratios of 13, 8, and 15 respectively, indicating their investment value in the current market environment, with long-term holding potentially yielding significant returns for investors.
See More
UPS Poised for Growth in Prescription Drug Delivery Market
- Market Growth Potential: UPS CEO Carol Tome indicated that despite the Iranian conflict clouding the global economic outlook, the company's efforts in the prescription drug delivery market are expected to yield benefits in the second half of the year, highlighting the recession-resistant nature of this sector.
- High Margin Business: The high profit margins in healthcare logistics, particularly for expensive medications with margins in the mid-to-high teens, are attracting UPS's focus, significantly aiding its transformation as it moves away from low-margin e-commerce deliveries.
- Historic Revenue Achievement: UPS reported a record $11.2 billion in healthcare revenue for 2025, accounting for nearly 13% of total revenue, with healthcare surpassing 14% in Q1 2026, demonstrating rapid growth in this segment.
- Strategic Transformation: Under CEO Tome's
See More
Three Undervalued Stocks to Consider Now
- Pfizer's Current Status: Pfizer's stock is currently priced around $25, and despite a 1% increase this year, investors have seen a 37% decline over the past five years due to slowing growth and patent expirations; however, the company is actively expanding its pipeline through acquisitions like Metsera, which could improve future performance.
- Novo Nordisk's Challenges: Novo Nordisk's GLP-1 drugs, Wegovy and Ozempic, have been approved and are generating significant revenue, but rising competition has led to a 4% decline in sales in the first quarter; nevertheless, strong demand for Wegovy and promising results from a higher-dose version may enhance future market share.
- PDD Holdings' Resilience: PDD Holdings' stock has dropped 17% this year, currently trading around $95, yet despite facing tariffs and trade uncertainties, sales for the last three months of 2025 increased by 12% to $17.7 billion, demonstrating the company's resilience, with potential for recovery if trade conditions improve.
- Investment Opportunities: Pfizer, Novo Nordisk, and PDD Holdings are all trading below their projected future earnings, with Pfizer at a P/E of 9, Novo Nordisk at 14, and PDD Holdings at just 8, presenting attractive buying opportunities for long-term investors amid current undervaluation.
See More
Chinese Stocks Rally Ahead of Trump-Xi Summit
- Market Recovery: Major Chinese companies including Alibaba, PDD, NetEase, and JD.com saw stock gains between 3% and 7% on Wednesday, reflecting market optimism ahead of the upcoming Trump-Xi summit.
- Small Caps Surge: Smaller Chinese firms like Dreamland Limited, Oriental Culture, and Antelope Enterprise experienced significant stock increases ranging from 25% to 67%, indicating strong investor interest and confidence in these companies.
- Summit Significance: The meeting between Trump and Xi marks their first encounter since 2017, with discussions expected to cover critical topics such as trade, policies, and national security, potentially providing clarity for global markets on future business conditions.
- Market Expectations: Investors on social media express optimism about the summit's outcomes, anticipating potential new tech deals between the U.S. and China, particularly involving Alibaba and Nvidia, which could attract significant market attention.
See More
Shein Accuses Temu of Large-Scale Copyright Infringement
- Copyright Infringement Allegations: Shein accuses Temu of using thousands of its photos to promote copies of its clothing, attempting to gain an unfair competitive advantage, highlighting the fierce rivalry in the global e-commerce market.
- Legal Counterclaims: Temu has dropped its defense against Shein's copyright claims over nearly 2,300 photos and has counterclaimed for damages after being forced to remove numerous product listings, illustrating the complexity of the legal battle.
- Competition Law Dispute: Temu alleges that Shein violated competition law by tying fast-fashion suppliers to exclusive agreements, with a trial on this matter scheduled for next year, which could impact industry supply chain dynamics.
- Changing Market Conditions: The removal of U.S. customs exemptions on low-value e-commerce parcels poses challenges for Shein and Temu's rapid expansion in international markets, potentially negatively affecting future growth.
See More
Analysis of VXUS ETF's 52-Week Price Fluctuations
- Price Range Analysis: The VXUS ETF has a 52-week low of $64.6035 and a high of $85.32, with the last trade at $85.19, indicating stability near its high point, which may attract investor interest in its price movements.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market sentiment.
See More
Three Growth Stocks to Consider Now
- Novo Nordisk's Challenges and Opportunities: Despite a 36% drop in share price over the past year, Novo Nordisk maintains strong profitability with a 33% gross margin and powerful assets like Ozempic and Wegovy, positioning it to benefit from growth in the GLP-1 market in the future.
- PDD Holdings' Market Potential: PDD Holdings has seen a 12% decline in stock price over the past year, yet reported a 12% revenue growth in the last three months of 2025, demonstrating resilience amid economic uncertainty, with Temu's popularity providing a foundation for future recovery.
- Intuit's Value Recovery: Although Intuit's stock has fallen 36% in the past year, its latest quarterly results show a 17% revenue increase, and its strong brand presence in accounting and tax software suggests it can leverage AI to enhance value moving forward.
- Investor Patience Rewarded: These three stocks currently have forward P/E ratios of 13, 8, and 15 respectively, indicating their investment value in the current market environment, with long-term holding potentially yielding significant returns for investors.
See More
UPS Poised for Growth in Prescription Drug Delivery Market
- Market Growth Potential: UPS CEO Carol Tome indicated that despite the Iranian conflict clouding the global economic outlook, the company's efforts in the prescription drug delivery market are expected to yield benefits in the second half of the year, highlighting the recession-resistant nature of this sector.
- High Margin Business: The high profit margins in healthcare logistics, particularly for expensive medications with margins in the mid-to-high teens, are attracting UPS's focus, significantly aiding its transformation as it moves away from low-margin e-commerce deliveries.
- Historic Revenue Achievement: UPS reported a record $11.2 billion in healthcare revenue for 2025, accounting for nearly 13% of total revenue, with healthcare surpassing 14% in Q1 2026, demonstrating rapid growth in this segment.
- Strategic Transformation: Under CEO Tome's
See More
